Tobam Buys Shares of 1,851 Amgen Inc. $AMGN

Tobam bought a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,851 shares of the medical research company’s stock, valued at approximately $606,000.

Several other hedge funds have also modified their holdings of AMGN. Vanguard Group Inc. boosted its holdings in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares in the last quarter. State Street Corp raised its stake in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Capital World Investors lifted its position in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. Capital International Investors lifted its position in Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after acquiring an additional 282,219 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ AMGN opened at $337.60 on Friday. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a market capitalization of $182.21 billion, a PE ratio of 23.49, a P/E/G ratio of 3.39 and a beta of 0.42. The company has a fifty day moving average of $340.71 and a 200 day moving average of $345.76.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on AMGN shares. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Royal Bank Of Canada boosted their target price on Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. UBS Group upped their target price on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Jefferies Financial Group initiated coverage on Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.